Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
E. N. Saykina
Observed names:
E.N. Saikina,
E.N. Saykina
Institutions:
Pirogov Russian National Research Medical University,
Russian Medical Academy of Continuous Professional Education,
Ministry of Health of the Russian Federation
Observed institutions:
Pirogov Russian National Research Medical University,
Russian Medical Academy of Continuous Professional Education,
Ministry of Health of the Russian Federation
ORCID:
0009-0003-4643-8489
Observed ORCID:
0009-0003-4643-8489
OpenAlex ID:
A5115573502
Computerized systems and databases for pharmacovigilance in Russia
2024
·
B. K. Romanov
, E. N. Saykina
, et al.
·
Real-World Data & Evidence
·
1
PDF
Facets of the efficacy of the selective sodiumglucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in the treatment of patients with cardiovascular diseases. Current data from clinical trials
2026
·
A.V. Vinogradova
, E.N. Saikina
, et al.
Modern glucose-lowering drugs SGLT2 inhibitors and GLP-1 agonists in the prevention of cardiovascular disease and dementia in patients with diabetes and metabolic disorders
2026
·
E. N. Saykina
, A. O. Kenkishvili
, et al.
·
Terapevt (General Physician)
Comparative safety of hypoglycemic drugs: sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors
2026
·
E. N. Saykina
, M. L. Maksimov
, et al.
Non-glycemic effects of dipeptidyl peptidase-4 inhibitors: efficacy and safety
2025
·
R. R. Minsafin
, E. N. Saykina
, et al.
·
Terapevt (General Physician)
Side effects of SGLT-2 inhibitors
2025
·
E.N. Saykina
, M.L. Maksimov
, et al.
·
Glavvrač (Chief Medical Officer)
Adverse reactions to SGLT-2 inhibitors in children with diabetes mellitus
2025
·
E. N. Saykina
, B. K. Romanov
, et al.
·
Terapevt (General Physician)
Show more works
View as search
Works count:
7
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type